NASDAQ$CMPX
Compass Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
CMPX Q2 2024 — $1.0M revenue
Company’s consolidated financial position as of June 30, 2024 and its consolidated results of operations, comprehensive loss and changes in stockholders’ equity for the three and six months. Compass Therapeutics Inc reported Q2 2024 results. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $1.0M.
- Operating income: $15K.
- Filed on Form 10-Q (accession 0001171843-24-004670).
Headline financials
Revenue & EPS history
Compass · Revenue · Quarterly
$850K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2024
-1.9%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-1.4%
Avg return
30 days after
47%
9 / 19 earnings
Positive
+10.3%
Q1 2023
Best reaction
-17.6%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.0% | -2.1% | -4.2% | |
| Q3 2025 | +1.1% | +12.9% | +45.9% | |
| Q1 2025 | +4.0% | +2.0% | +19.3% | |
| Q4 2024 | -1.7% | -6.4% | -33.0% | |
| Q3 2024 | -11.1% | -27.4% | -20.5% | |
| Q2 2024 | +10.1% | +6.4% | +37.6% | |
| Q1 2024 | +1.3% | +0.0% | -25.0% | |
| Q4 2023 | +0.5% | -6.6% | -30.7% | |
| Q3 2023 | -9.9% | -11.0% | +1.2% | |
| Q2 2023 | -3.8% | -5.3% | -9.2% | |
| Q1 2023 | +10.3% | +13.3% | -1.8% | |
| Q4 2022 | -5.0% | -10.8% | -13.9% | |
| Q3 2022 | -4.0% | +10.4% | +1.4% | |
| Q2 2022 | +1.2% | +2.3% | +5.8% | |
| Q1 2022 | -3.0% | +50.3% | +63.9% | |
| Q4 2021 | +6.2% | +4.6% | +20.8% | |
| Q3 2021 | +0.3% | +7.2% | -16.2% | |
| Q2 2021 | -11.9% | -6.0% | -16.7% | |
| Q1 2021 | -17.6% | -17.6% | -50.6% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro